<DOC>
	<DOCNO>NCT02268045</DOCNO>
	<brief_summary>Study RTXM83 plus CHOP chemotherapy versus rituximab plus CHOP therapy patient Non Hodgkin 's lymphoma The primary endpoint investigation determine response rate obtain RXM83 combine CHOP non inferior response rate obtain reference rituximab combine CHOP The present study non inferiority trial study hypothesis follow : H0 : pc ≥ pe + δ vs. H1 : pc &lt; pe + δ , pe : proportion successes experimental group ( RTXM83+CHOP ) pc : proportion success control group ( Reference Rituximab+CHOP ) Type I error : difference pc-pe less δ fact difference great equal δ ie , investigator choose experimental treatment control treatment actually substantially good . Type II error : difference -pe great equal δ actually l δ ie , investigator choose control treatment experimental treatment essentially good .</brief_summary>
	<brief_title>Study RTXM83 Plus CHOP Chemotherapy Versus Rituximab Plus CHOP Therapy Patients With Non Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Patients measurable disease define existence unidimensional bidimensional lesion great 2 cm long diameter malignant lymphocytosis great 5x109/L . Any procedure measurable disease particular case , may allow upon Sponsor approval 2 . Newly diagnose patient confirm pathologic diagnosis large B cellnonHodgkin 's lymphoma ( DLBCL ) untreated CD20+ . Defined local Haematopathologist local laboratory accord WHO criteria 3 . Stage IIIII IV stage I bulk defined refer physician basis Cotswolds modification Ann Arbor classification 2 4 . Ageadjusted International Prognostic Index ( IPI ) score 0 1 5 . Age ≥18 ≤65 year age 6 . Performance status ( Eastern Cooperative Oncology Group [ ECOG ] ) ≤2 7 . Written inform consent obtain start studyspecific procedure 8 . Females childbearing potential must test negative standard serum pregnancy test must willing practice appropriate contraceptive method duration study ( e.g . oral contraceptive , double barrier method , intrauterine device , intramuscular contraceptive ) 9 . All male patient must take adequate contraceptive precaution course study 1 . Life expectancy less three month 2 . Any lymphoma CD20+ DLBCL 3 . Indolent lymphoma , Primary central nervous system ( CNS ) Lymphoma gastrointestinal Mucosa Associated Lymphoid Tissue ( MALT ) Lymphoma 4 . Known hypersensitivity active ingredient , excipients murine foreign proteins 5 . Concurrent disease general status would exclude give treatment outline protocol 6 . Active uncontrolled infection require systemic treatment antibiotic antiviral agent Screening history document recurrent clinically significant infection ( e.g . 2 viral , bacterial fungal infection require inpatient treatment ) 7 . Cardiac contraindication Doxorubicin therapy : noncompensated heart failure , dilate cardiomyopathy , coronary heart disease ST segment depression electrocardiogram ( ECG ) , myocardial infarction last 6 month 8 . Neurologic contraindication Vincristine indicate SmPC : ( e.g . peripheral neuropathy ) 9 . Chronic lung disease hypoxemia measure saturometer ( gasometry mandatory ) 10 . Severe uncontrolled hypertension , despite optimal medical treatment 11 . Severe uncontrolled diabetes mellitus , despite optimal medical treatment 12 . Renal insufficiency ( Serum Creatinine &gt; 2xUNL ) 13 . Hepatic insufficiency ( aspartate aminotransferase [ AST ] /alanine aminotransferase [ ALT ] &gt; 3xUNL &gt; 5xUNL involvement liver , total bilirubin &gt; 34.2 µmol/L , ) relate lymphoma 14 . Clinical sign cerebral dysfunction 15 . Severe psychiatric disease 16 . Known human immunodeficiency virus ( HIV ) infection active chronic hepatitis B C 17 . Abnormal bone marrow function ( platelet &lt; 100x109/L , neutrophil &lt; 1.5x109/L Haemoglobin &lt; 9g/dL ) 18 . Posttransplantation lymphoproliferative disease 19 . Pregnant lactate woman woman intend get pregnant study within 12 month follow last infusion 20 . Treatment investigational product 30 day period inclusion study 21 . Prior radiotherapy treat DLBCL NHL 22 . Limitation patient 's ability comply treatment followup protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Diffuse large b-cell lymphoma</keyword>
</DOC>